Education
About Us
Working with TipRanks
Follow Us
Sagimet Biosciences, Inc. Class A (SGMT)
NASDAQ:SGMT
SGMT Stock Chart & Stats
$7.52
-$0.58(-10.41%)
At close: 4:00 PM EST
$7.52
-$0.58(-10.41%)
Day’s Range― - ―
52-Week Range$1.73 - $11.41
Previous CloseN/A
Volume1.06M
Average Volume (3M)560.16K
Market Cap
$238.40M
Enterprise Value$120.07M
Total Cash (Recent Filing)$125.41M
Total Debt (Recent Filing)$152.00K
Price to Earnings (P/E)―
Beta3.28
Next Earnings
Nov 12, 2025EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding31,001,108
10 Day Avg. Volume699,080
30 Day Avg. Volume560,159
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)0.91
Price to Sales (P/S)0.00
P/FCF Ratio-3.32
Enterprise Value/Market Cap0.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.85
Forecast
1Y Price Target
$27.29Price Target Upside262.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.67
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentSagimet announced that the Phase I PK study of the combination therapy with denifanstat, the company's FASN inhibitor, and a THR-β agonist, resmetirom, has dosed the first patient.
Financial StabilitySagimet Biosciences has enough cash, $135 million, to support operations through the completion of Phase 1 trials, indicating financial stability.
Strategic PositioningDenifanstat is viewed as an extremely competitive alternative to oral antibiotics for acne treatment, with a favorable risk-benefit profile.
Bears Say
Financial PerformanceThe company reported a net loss of $10.4 million in the second quarter, which may be a concern for investors.
Investor ConcernsDenifanstat treatment led to significant fibrosis improvement without MASH worsening vs. placebo (>20% absolute difference), which should benefit patients with more advanced fibrosis (F4).
Sagimet Biosciences, Inc. Class A News
SGMT FAQ
What was Sagimet Biosciences, Inc. Class A’s price range in the past 12 months?
Sagimet Biosciences, Inc. Class A lowest stock price was $1.73 and its highest was $11.41 in the past 12 months.
What is Sagimet Biosciences, Inc. Class A’s market cap?
Sagimet Biosciences, Inc. Class A’s market cap is $238.40M.
When is Sagimet Biosciences, Inc. Class A’s upcoming earnings report date?
Sagimet Biosciences, Inc. Class A’s upcoming earnings report date is Nov 12, 2025 which is in 3 days.
How were Sagimet Biosciences, Inc. Class A’s earnings last quarter?
Sagimet Biosciences, Inc. Class A released its earnings results on Aug 13, 2025. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.508 by $0.188.
Is Sagimet Biosciences, Inc. Class A overvalued?
According to Wall Street analysts Sagimet Biosciences, Inc. Class A’s price is currently Undervalued.
Does Sagimet Biosciences, Inc. Class A pay dividends?
Sagimet Biosciences, Inc. Class A does not currently pay dividends.
What is Sagimet Biosciences, Inc. Class A’s EPS estimate?
Sagimet Biosciences, Inc. Class A’s EPS estimate is -0.39.
How many shares outstanding does Sagimet Biosciences, Inc. Class A have?
Sagimet Biosciences, Inc. Class A has 31,001,108 shares outstanding.
What happened to Sagimet Biosciences, Inc. Class A’s price movement after its last earnings report?
Sagimet Biosciences, Inc. Class A reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.508. Following the earnings report the stock price went up 0.314%.
Which hedge fund is a major shareholder of Sagimet Biosciences, Inc. Class A?
Currently, no hedge funds are holding shares in SGMT
Sagimet Biosciences, Inc. Class A Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.29 (262.90% Upside)
$27.29 (262.90% Upside)
Blogger Sentiment
Bullish
SGMT Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.48%
12-Months-Change
Fundamentals
Return on Equity
-37.89%
Trailing 12-Months
Asset Growth
-27.31%
Trailing 12-Months
Company Description
Sagimet Biosciences, Inc. Class A
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
SGMT Stock 12 Month Forecast
Average Price Target
$27.29
▲(262.90% Upside)
Technical Analysis
Codexis
―
Cabaletta Bio
―
Black Diamond Therapeutics
―
Atea Pharmaceuticals
―
Entrada Therapeutics Inc
―
Ownership Overview
10.15% Insiders
6.58% Mutual Funds
<0.01% Other Institutional Investors
79.66% Public Companies and Individual Investors